American Italian Pasta
American Italian Pasta Newswire

American Italian Pasta Newswire

Comprehensive Real-Time News Feed for American Italian Pasta.

Results 1 - 19 of 19 in American Italian Pasta

  1. New Market Report: Low Back Pain - Pipeline Review, H1 2015Read the original story w/Photo

    Monday Aug 24 | PR-inside.com

    Global Markets Direct's, 'Low Back Pain - Pipeline Review, H1 2015', provides an overview of the Low Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type, along with latest updates, and featured news and press releases.

    Comment?

  2. Low Back Pain - Pipeline Review, H1 2015; New Report LaunchedRead the original story w/Photo

    Jul 15, 2015 | SBWire

    Low Back Pain - Pipeline Review, H1 2015 provides an overview of the Low Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type, along with latest updates, and featured news and press releases.

    Comment?

  3. Antibe Therapeutics Inc. Announces Change In CFO Position And Granting Of Employee Stock OptionsRead the original story

    Jul 12, 2015 | BioSpace

    Antibe Therapeutics Inc. today announced that Dr. Michael Bumby has resigned as CFO, effective August 1, 2015. Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013.

    Comment?

  4. Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock OptionsRead the original story

    Jul 13, 2015 | Business Wire

    Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013. Samira Sakhia has been named the Company's CFO on an interim basis replacing Dr. Bumby.

    Comment?

  5. New Study: Corporate Tax Rate Most Important Single Factor for InvestmentRead the original story w/Photo

    Jul 9, 2015 | Tax Foundation

    Multinational corporations , intergovernmental organizations , and academics know that high levels of corporate taxation serve as a disincentive for foreign direct investment . Companies shift resources toward countries that provide the most business-friendly climate and away from those nations more hostile to investment.

    Comment?

  6. Ariad And Paladin Labs Inc. Announce Commercial Distribution...Read the original story

    Jun 9, 2015 | BioSpace

    CAMBRIDGE, Mass., & MONTREAL-- --ARIAD Pharmaceuticals, Inc. and Paladin Labs Inc., an operating company of Endo International plc , today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusiga in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

    Comment?

  7. ARIAD and Paladin Announce Commercial Distribution Agreement for...Read the original story w/Photo

    Jun 10, 2015 | Investor's Business Daily

    CAMBRIDGE, Mass., & MONTREAL-- -- ARIAD Pharmaceuticals, Inc. and Paladin Labs Inc., an operating company of Endo International plc , today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusiga in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

    Comment?

  8. Husch adds new food and agribusiness partnerRead the original story w/Photo

    Jun 1, 2015 | Business Journal

    ... Sprungli AG; the $2.2 billion merger between Applebee's and IHOP; and the $1.2 billion merger between American Italian Pasta and Ralcorp. The firm's team has more than 50 attorneys.

    Comment?

  9. Endo To Purchase Par PharmaceuticalsRead the original story

    May 21, 2015 | Chemical and Engineering News

    In the latest consolidation move in the generics industry, the Irish specialty drug firm Endo will pay $8.1 billion to buy U.S.-based Par Pharmaceutical . Together, Endo and Par will be number five in U.S. generics sales.a Includes some Canadian sales.

    Comment?

  10. Endo To Purchase Par PharmaceuticalRead the original story w/Photo

    May 18, 2015 | Chemical and Engineering News

    Endo , a specialty drug firm based in Ireland, will pay $8.1 billion in cash and stock to acquire the U.S.-based generic drug firm Par Pharmaceutical . The combined business will have about $4.2 billion in annual sales.

    Comment?

  11. Endo Pharmaceuticals Posts A Solid Q1 Earnings ReportRead the original story

    May 12, 2015 | GuruFocus.com

    Global specialty healthcare company Endo Pharmaceuticals released its first-quarter results for the fiscal year 2015 on May 11 in the pre-market hours. The higher-than-expected adjusted earnings came in as the company completed a series of acquisitions during the quarter.

    Comment?

  12. Knight Therapeutics: A solid long-term bet in the health care spaceRead the original story w/Photo

    May 5, 2015 | Globe and Mail

    Jonathan Ross Goodman, president and CEO of Knight Therapeutics. Knight's rich valuation isn't only about sector rotation into health care - it's a bet on Mr. Goodman, who is famous in investment circles for building Paladin Labs over almost two decades and then selling it to Endo Health Solutions for a total stock return of 9,000 per cent.

    Comment?

  13. Comings & Goings: News DigestRead the original story w/Photo

    May 3, 2015 | Wall Street Journal

    Commercial real-estate and securities lawyer Gerald D. Shepherd is joining Arnold & Porter LLP as a partner in the international firm's New York office. Mr. Shepherd, a graduate of Columbia University School of Law, comes to Arnold & Porter from Davies Ward Phillips & Vineberg LLP, where he advised private-equity and real-estate funds in connection with ventures, acquisitions and financings.

    Comment?

  14. FDA Pulls Approval for Dog Antifreeze AntidoteRead the original story w/Photo

    Apr 14, 2015 | Pet Product News

    The U.S. Food and Drug Administration withdrew approval for Antizol-Vet, an antidote for antifreeze poisoning in dogs available through veterinarians, at the request of the drug's sponsor, Paladin Labs Inc. Paladin Labs requested that the FDA withdraw the approval because the company has not manufactured or marketed the drug since Oct. 1, 2014. The most recent lot marketed in the U.S. is lot #1319-12A with an expiration date of August 2017.

    Comment?

  15. FDA Withdraws Antifreeze Antidote for Dogs ApprovalRead the original story w/Photo

    Apr 7, 2015 | Kansas City InfoZine

    Washington DC - infoZine - The U.S. Food and Drug Administration is announcing that it has withdrawn the approval for Antizol-Vet, also known as fomepizole, 4-methylpyrazole, or 4-MP, at the request of the drug's sponsor. Originally approved by FDA in 1996, Antizol-Vet is an antidote for ethylene glycol poisoning in dogs.

    Comment?

  16. SQI Diagnostics Appoints Chief Financial OfficerRead the original story

    Mar 3, 2015 | Sys-Con Media

    In his capacity as CFO he will assist the Company in its transition from a development stage to a commercially successful company including strategic financing initiatives to advance the Company's capital market strategy and to secure funding to drive future growth and further expansion of SQI proprietary technologies. "The extensive experience Lennie brings to SQI is well-aligned with our financial objectives.

    Comment?

  17. Exclusive - Drugmaker Endo vying for Salix takeover: sourceRead the original story

    Feb 13, 2015 | West Australian

    Endo, which makes drugs that focus on pain management, and its advisers have sent several letters to the company, and it remains interested in a potential takeover, said the person, who asked not to be identified because the deliberations are confidential. have also taken steps towards a bid for Salix, sources previously told Reuters.

    Comment?

  18. Looking For Opportunity In Endo's Structural ChangesRead the original story w/Photo

    Feb 5, 2015 | Seeking Alpha

    Endo International is an Ireland-based company that manufactures and sells medicines. Lidoderm, Opana, Voltaren and Percocet contributed more than 943.5 mln USD in net sales during the first 9 months of 2013.

    Comment?

  19. Morris Animal Foundation Welcomes New Chairman and TrusteesRead the original story w/Photo

    Jan 20, 2015 | GlobeNewswire

    ... Walt George recently retired as Corporate Vice President of Ralcorp Holdings Inc. and President of American Italian Pasta Company . He now devotes his time to small business consulting and serves on advisory boards for both corporate and nonprofit ...

    Comment?